skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.02d (Release date: 2016-02-27)
SearchBox Top
SearchBox Bottom
L-377,202 (Code C1853)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: L-377,202

Definition: A prodrug in which a peptide is covalently conjugated with the anthracycline antineoplastic antibiotic doxorubicin. This complex is hydrolyzed by the enzyme prostate-specific antigen (PSA), resulting in the formation of doxorubicin and leucine-doxorubicin. Selective targeting of these drugs to prostate tumor cells occurs because the hydrolyzing PSA enzyme is localized to the prostate gland. Doxorubicin and leucine-doxorubicin intercalate into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. These agents also produce toxic free-radical intermediates and interact with cell membrane lipids causing lipid peroxidation. (NCI04)

NCI-GLOSS Definition: A substance that is being studied in the treatment of cancer.

Label: L-377,202

NCI Thesaurus Code: C1853 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0879383  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
PDQ Closed Trial Search ID 37792
PDQ Open Trial Search ID 37792 (check for NCI PDQ open clinical trial info)
UMLS CUI C0879383

Other Properties:
Name Value (qualifiers indented underneath)
code C1853
Legacy_Concept_Name L-377_202
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Antibiotic

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom